Hemostemix Inc. announce the results of its Phase II Clinical Trial and the results of a new retrospective study of patients that underwent a trans-catheter, intramyocardial injection of angiogenic cell precursors (ACP-01) as a treatment for heart failure (ischemic and non-ischemic dilated cardiomyopathy). At first follow-up (average 4 months) after ACP-01 cell implantation, for all types of heart failure, the LVEF was increased by 4.6% (from 28.6% to 33.2%), representing a statistically significant improvement (p = 0.0011). On final follow-up (average 12 months after cell implantation) for all patients, the LVEF% had improved by 7.69%, which was statistically significant (p=0.003).

When analyzing ischemic heart failure alone (n=41), LVEF increased from 29.9% before implantation, to 34.5%, and to 38.2% at final follow-up, for an overall improvement of 8.37%, which was statistically significant (p= 0.003). There was greater improvement in the non-ischemic dilated cardiomyopathy patients (n=8), who improved from 25.94% before treatment to 40.29% at final follow-up, for an overall improvement of 14.35% (p=0. 002).